Abraxis BioScience, Inc, a fully integrated, global biotechnology company, announced that the board of directors has approved a strategic plan to create Abraxis Health, Inc, an independent, stand-alone company to be spun-off from Abraxis BioScience that will be dedicated to becoming a fully integrated, next-generation, evidence-based, personalized healthcare company.
"The opportunity that lies in front of Abraxis BioScience is enormous and is a result of the validated science underlying the company’s proprietary nabs technology in the clinical setting," said Patrick Soon-Shiong, chairman and chief executive officer of Abraxis BioScience. "In 2009, we plan to initiate nine pivotal registrational trials in multiple tumour types, including breast cancer, lung, melanoma and pancreatic cancers. In addition, Abraxis has initiated 65 investigator-sponsored phase-2 studies and 16 phase-1 studies. Together with the current approval of Abraxane in 36 countries and the continuing need to establish infrastructure for the global launch of this compound, the immense and exciting task that lies ahead should be the primary focus of Abraxis BioScience."
Abraxis BioScience will be solely dedicated to building its Abraxane franchise on a global basis, advancing an extensive phase-3 clinical programme, and leveraging its proprietary nab technology platform. For the nine months ended September 30, 2008, Abraxis reported revenue from sales of Abraxane of $245.8 million.
Abraxis Health has been created to focus on generating biological systems and advancing personalized medicine through strategic alliances and internal development.
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses.